New patent for the Janssen Pharms drug INVOKAMET – DrugPatentWatch
Annual Drug Patent Expiration for INVOKAMET
Invokamet is a drug marketed by Janssen Pharms and is included in two NDAs. It is available from a single supplier. There are five patents protecting this drug and two Paragraph IV challenges.
INVOKAMET drug price trends.
Drug patent litigation for INVOKAMET.
This drug has two hundred and six patent family members in forty-five countries.
The generic ingredient in INVOKAMET is canagliflozin; metformin hydrochloride. One registered supplier for this compound. Additional details are available on canagliflozin; metformin hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Make Better Decisions with DrugPatentWatch
» Start Your Free Trial Today «
Copyright © DrugPatentWatch. Originally published in New patent for the Janssen Pharms drug INVOKAMET
